Godsey & Gibb Inc. Increases Holdings in Amgen Inc. (NASDAQ:AMGN)

Godsey & Gibb Inc. grew its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 3.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 64,718 shares of the medical research company's stock after acquiring an additional 2,041 shares during the quarter. Godsey & Gibb Inc.'s holdings in Amgen were worth $16,868,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. State Street Corp lifted its position in Amgen by 1.2% during the 3rd quarter. State Street Corp now owns 29,317,018 shares of the medical research company's stock worth $9,446,236,000 after acquiring an additional 345,537 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Amgen by 0.9% during the third quarter. Geode Capital Management LLC now owns 12,122,889 shares of the medical research company's stock worth $3,893,771,000 after purchasing an additional 103,851 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Amgen by 2.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 10,532,629 shares of the medical research company's stock valued at $3,393,718,000 after buying an additional 251,876 shares during the last quarter. Janus Henderson Group PLC boosted its position in Amgen by 11.7% in the third quarter. Janus Henderson Group PLC now owns 5,143,330 shares of the medical research company's stock valued at $1,657,183,000 after buying an additional 538,545 shares during the last quarter. Finally, Pathway Financial Advisers LLC increased its holdings in Amgen by 33,125.4% in the 3rd quarter. Pathway Financial Advisers LLC now owns 4,460,181 shares of the medical research company's stock worth $1,437,115,000 after buying an additional 4,446,757 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have commented on AMGN shares. Leerink Partners decreased their price objective on shares of Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. UBS Group decreased their target price on shares of Amgen from $335.00 to $326.00 and set a "neutral" rating for the company in a research report on Thursday, October 31st. Wells Fargo & Company cut their price target on Amgen from $335.00 to $280.00 and set an "equal weight" rating on the stock in a research report on Friday, January 10th. TD Cowen boosted their price objective on Amgen from $381.00 to $383.00 and gave the company a "buy" rating in a report on Monday, October 21st. Finally, Bank of America reaffirmed an "underperform" rating and set a $256.00 target price on shares of Amgen in a report on Tuesday, December 10th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $314.91.

Amgen Price Performance

NASDAQ:AMGN traded up $0.49 during trading hours on Thursday, hitting $269.43. 2,684,349 shares of the stock were exchanged, compared to its average volume of 3,105,385. The company has a market cap of $144.83 billion, a P/E ratio of 34.50, a P/E/G ratio of 2.68 and a beta of 0.56. The firm's fifty day moving average price is $276.06 and its 200 day moving average price is $307.76. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to analysts' expectations of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm's revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the previous year, the business earned $4.96 earnings per share. As a group, equities research analysts anticipate that Amgen Inc. will post 19.57 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. This is an increase from Amgen's previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.53%. The ex-dividend date is Friday, February 14th. Amgen's dividend payout ratio (DPR) is currently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.